⏱ 1 min 30 read
Background
Bioscibex is a spin-off of the Swiss Federal Institute of Technology in Lausanne (EPFL) founded in 2024. Based at the BioArk in Monthey, in Valais, it has developed SW1NGO, a bioreactor for the biopharmaceutical industry. The start-up had already obtained CHF 100,000 from Venture Kick and, in June 2026, the BCVS Prix Créateurs.
The key points
Bioscibex obtains the support ofInnosuisse, the Swiss Innovation Agency, for a project worth CHF 1.026 million , according to Le Nouvelliste of 10 November 2026. Innosuisse can cover up to 70% of the direct costs of this type of project; the company funds the balance.
This funding should accelerate the commercialisation of SW1NGO in Europe. This single-use bioreactor combines in a single device the cell culture steps needed to manufacture biological medicines. It thus limits handling and the risk of contamination. The first machines have been delivered in Switzerland and abroad to major biopharmaceutical groups.
Key figures
- CHF 1.026 million francs: total amount of the project supported by Innosuisse
- 70 % : maximum share of direct costs covered by Innosuisse
- CHF 100,000 : funding obtained through Venture Kick
- CHF 25,000 : BCVS Prix Créateurs won in June 2026
What it means for businesses
- Biopharmaceutical groups : they are studying the integration of SW1NGO into their production processes
- BioArk in Monthey : the Valais site hosts a start-up in its European roll-out phase
Who says what
- Chloé Albietz (CEO of Bioscibex): the support should accelerate European roll-out while meeting customers’ regulatory requirements
Further reading
Sources
Let’s share Romandy’s news
We build the news together.
An idea, an opinion, a wish, a detail to add? Tell us!
